{"id":22172,"date":"2025-10-07T12:33:15","date_gmt":"2025-10-07T12:33:15","guid":{"rendered":"https:\/\/itbusinesstoday.com\/?p=22172"},"modified":"2025-10-07T12:33:15","modified_gmt":"2025-10-07T12:33:15","slug":"eisai-and-biogen-introduce-leqembi-iqlik-for-alzheimer","status":"publish","type":"post","link":"https:\/\/itbusinesstoday.com\/ja\/health-tech\/pharma\/eisai-and-biogen-introduce-leqembi-iqlik-for-alzheimer\/","title":{"rendered":"\u30a8\u30fc\u30b6\u30a4\u3068\u30d0\u30a4\u30aa\u30b8\u30a7\u30f3\u3001\u30a2\u30eb\u30c4\u30cf\u30a4\u30de\u30fc\u578b\u8a8d\u77e5\u75c7\u6cbb\u7642\u85acLEQEMBI IQLIK\u3092\u767a\u8868"},"content":{"rendered":"<?xml encoding=\"utf-8\" ?><p>Eisai Co., Ltd. and Biogen Inc. LEQEMBI&reg; IQLIK&trade; (lecanemab-irmb) is now available in the U.S. It&rsquo;s a subcutaneous injection for treating early Alzheimer&rsquo;s disease (AD). It includes people with mild cognitive impairment (MCI) and mild dementia. This new option comes after an 18-month IV treatment with LEQEMBI. Patients can choose to keep their IV doses every four weeks or switch to a weekly 360 mg subcutaneous injection. They can use the LEQEMBI IQLIK autoinjector for this.<\/p><p>\u30a8\u30fc\u30b6\u30a4\u3068 <a href=\"https:\/\/www.biogen.com\/\" data-no-translation=\"\">Biogen<\/a> have launched the LEQEMBI Companion&trade; program to support patients during treatment. This program offers various resources, such as:<\/p><ul>\n<li>\u770b\u8b77\u6559\u80b2\u8005\u306b\u3088\u308b\u6559\u80b2\u652f\u63f4<\/li>\n<li>\u30b1\u30a2\u30fb\u30d1\u30fc\u30c8\u30ca\u30fc\u306e\u305f\u3081\u306e\u30a6\u30a7\u30eb\u30ab\u30e0\u30fb\u30ad\u30c3\u30c8<\/li>\n<li>\u30e1\u30c7\u30a3\u30bb\u30fc\u30d5\u3068\u5171\u306b\u5275\u3089\u308c\u305f\u30c7\u30b8\u30bf\u30eb\u30d7\u30e9\u30c3\u30c8\u30d5\u30a9\u30fc\u30e0<\/li>\n<\/ul><p>\u3053\u308c\u3089\u306e\u30c4\u30fc\u30eb\u306f\u3001\u60a3\u8005\u3068\u305d\u306e\u5bb6\u65cf\u304c\u65c5\u3092\u30ca\u30d3\u30b2\u30fc\u30c8\u3059\u308b\u306e\u3092\u52a9\u3051\u308b\u3053\u3068\u3092\u76ee\u7684\u3068\u3057\u3066\u3044\u307e\u3059\u3002<\/p><p>The program helps patients by tracking injections. It teaches them how to administer at home. Patients can also get guidance on insurance and financial support. Eligible patients may also receive LEQEMBI at no cost through Eisai&rsquo;s Patient Assistance Program (PAP).<\/p><h4>\u3053\u3061\u3089\u3082\u304a\u8aad\u307f\u304f\u3060\u3055\u3044\uff1a <a class=\"p-url\" href=\"https:\/\/itbusinesstoday.com\/ja\/health-tech\/pharma\/cm-plus-launches-pharmo-ai-for-pharma-research-support\/\" rel=\"bookmark\">CM Plus launches &ldquo;pharmo.AI&rdquo; for pharma research support<\/a><\/h4><p>LEQEMBI IQLIK lets you take treatment at home. This cuts down on time and reduces the need for infusion centers. It may also help healthcare resources become available for new patients. The therapy focuses on amyloid-beta protofibrils and plaques. These are key players in the neurodegenerative process of Alzheimer&rsquo;s disease (AD). It aims to slow down disease progression by keeping its effects going after the first 18-month IV course.<\/p><p>Alzheimer&rsquo;s disease leads to the buildup of amyloid plaques and tau tangles. These cause damage to neurons and result in cognitive decline. LEQEMBI targets both pathologies. Keep your brain sharp longer with LEQEMBI&rsquo;s dual-action benefits.<\/p><p>LEQEMBI is indicated for patients with MCI or mild dementia due to Alzheimer&rsquo;s disease. <a href=\"https:\/\/www.eisai.com\/\" data-no-translation=\"\">Eisai<\/a> \u304c\u30b0\u30ed\u30fc\u30d0\u30eb\u306a\u958b\u767a\u3068\u627f\u8a8d\u7533\u8acb\u3092\u884c\u3044\u307e\u3059\u3002\u4e00\u65b9\u3001\u30a8\u30fc\u30b6\u30a4\u3068\u30d0\u30a4\u30aa\u30b8\u30a7\u30f3\u306f\u3001\u7c73\u56fd\u306b\u304a\u3051\u308b\u672c\u6cbb\u7642\u85ac\u306e\u5171\u540c\u8ca9\u58f2\u3068\u30d7\u30ed\u30e2\u30fc\u30b7\u30e7\u30f3\u3092\u884c\u3044\u307e\u3059\u3002<\/p>","protected":false},"excerpt":{"rendered":"<p>Eisai Co., Ltd. and Biogen Inc. LEQEMBI&reg; IQLIK&trade; (lecanemab-irmb) is now available in the U.S. It&rsquo;s a subcutaneous injection for treating early Alzheimer&rsquo;s disease (AD). It includes people with mild cognitive impairment (MCI) and mild dementia. This new option comes after an 18-month IV treatment with LEQEMBI. Patients can choose to keep their IV doses every four weeks or switch to a weekly 360 mg subcutaneous injection. They can use the LEQEMBI IQLIK autoinjector for this.Eisai and Biogen have launched the LEQEMBI Companion&trade; program to support patients during treatment. This program offers various resources, such as: Educational support from nurse educators A welcome kit for care partners A digital platform [&hellip;]<\/p>\n","protected":false},"author":7,"featured_media":22173,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_bbp_topic_count":0,"_bbp_reply_count":0,"_bbp_total_topic_count":0,"_bbp_total_reply_count":0,"_bbp_voice_count":0,"_bbp_anonymous_reply_count":0,"_bbp_topic_count_hidden":0,"_bbp_reply_count_hidden":0,"_bbp_forum_subforum_count":0,"wprm-recipe-roundup-name":"","wprm-recipe-roundup-description":"","postBodyCss":"","postBodyMargin":[],"postBodyPadding":[],"postBodyBackground":{"backgroundType":"classic","gradient":""},"footnotes":""},"categories":[208,89,211,237,182,206],"tags":[872,7394,1715,8340,424],"ppma_author":[572],"class_list":["post-22172","post","type-post","status-publish","format-standard","has-post-thumbnail","category-apac","category-health-tech","category-japan","category-news","category-pharma","category-regional","tag-alzheimer-disease","tag-biogen","tag-eisai","tag-leqembi-iqlik","tag-pharma"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Eisai &amp; Biogen Launch LEQEMBI IQLIK Injection<\/title>\n<meta name=\"description\" content=\"Eisai and Biogen launch LEQEMBI\u00ae IQLIK\u2122, a weekly subcutaneous injection for early Alzheimer\u2019s, offering an alternative to IV treatment.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/itbusinesstoday.com\/ja\/health-tech\/pharma\/eisai-and-biogen-introduce-leqembi-iqlik-for-alzheimer\/\" \/>\n<meta property=\"og:locale\" content=\"ja_JP\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Eisai &amp; Biogen Launch LEQEMBI IQLIK Injection\" \/>\n<meta property=\"og:description\" content=\"Eisai and Biogen launch LEQEMBI\u00ae IQLIK\u2122, a weekly subcutaneous injection for early Alzheimer\u2019s, offering an alternative to IV treatment.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/itbusinesstoday.com\/ja\/health-tech\/pharma\/eisai-and-biogen-introduce-leqembi-iqlik-for-alzheimer\/\" \/>\n<meta property=\"og:site_name\" content=\"itbusinesstoday\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-07T12:33:15+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/10\/Eisai-and-Biogen-Announce-U.S.-Availability-of-LEQEMBI\u00ae-IQLIK\u2122-lecanemab-irmb-Subcutaneous-Injection-Maintenance-Dose-for-Treatment-of-Early-Alzheimers-Disease.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"800\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"ITBT StaffWriter\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u57f7\u7b46\u8005\" \/>\n\t<meta name=\"twitter:data1\" content=\"ITBT StaffWriter\" \/>\n\t<meta name=\"twitter:label2\" content=\"\u63a8\u5b9a\u8aad\u307f\u53d6\u308a\u6642\u9593\" \/>\n\t<meta name=\"twitter:data2\" content=\"2\u5206\" \/>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"\u30a8\u30fc\u30b6\u30a4\u3068\u30d0\u30a4\u30aa\u30b8\u30a7\u30f3\u3001LEQEMBI IQLIK\u6ce8\u5c04\u5264\u3092\u65b0\u767a\u58f2","description":"\u30a8\u30fc\u30b6\u30a4\u3068\u30d0\u30a4\u30aa\u30b8\u30a7\u30f3\u793e\u3001\u65e9\u671f\u30a2\u30eb\u30c4\u30cf\u30a4\u30de\u30fc\u578b\u8a8d\u77e5\u75c7\u6cbb\u7642\u5264\u300cLEQEMBI\u00ae IQLIK\u2122\u300d\u3092\u90311\u56de\u76ae\u4e0b\u6ce8\u88fd\u5264\u3068\u3057\u3066\u767a\u58f2\u3001\u70b9\u6ef4\u9759\u6ce8\u306b\u4ee3\u308f\u308b\u6cbb\u7642\u6cd5\u3092\u63d0\u4f9b.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/itbusinesstoday.com\/ja\/health-tech\/pharma\/eisai-and-biogen-introduce-leqembi-iqlik-for-alzheimer\/","og_locale":"ja_JP","og_type":"article","og_title":"Eisai & Biogen Launch LEQEMBI IQLIK Injection","og_description":"Eisai and Biogen launch LEQEMBI\u00ae IQLIK\u2122, a weekly subcutaneous injection for early Alzheimer\u2019s, offering an alternative to IV treatment.","og_url":"https:\/\/itbusinesstoday.com\/ja\/health-tech\/pharma\/eisai-and-biogen-introduce-leqembi-iqlik-for-alzheimer\/","og_site_name":"itbusinesstoday","article_published_time":"2025-10-07T12:33:15+00:00","og_image":[{"width":1200,"height":800,"url":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/10\/Eisai-and-Biogen-Announce-U.S.-Availability-of-LEQEMBI\u00ae-IQLIK\u2122-lecanemab-irmb-Subcutaneous-Injection-Maintenance-Dose-for-Treatment-of-Early-Alzheimers-Disease.webp","type":"image\/webp"}],"author":"ITBT StaffWriter","twitter_card":"summary_large_image","twitter_misc":{"\u57f7\u7b46\u8005":"ITBT StaffWriter","\u63a8\u5b9a\u8aad\u307f\u53d6\u308a\u6642\u9593":"2\u5206"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/eisai-and-biogen-introduce-leqembi-iqlik-for-alzheimer\/#article","isPartOf":{"@id":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/eisai-and-biogen-introduce-leqembi-iqlik-for-alzheimer\/"},"author":{"name":"ITBT StaffWriter","@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#\/schema\/person\/94fb575e469aff25a4b938814d050f15"},"headline":"Eisai and Biogen introduce LEQEMBI IQLIK for Alzheimer","datePublished":"2025-10-07T12:33:15+00:00","mainEntityOfPage":{"@id":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/eisai-and-biogen-introduce-leqembi-iqlik-for-alzheimer\/"},"wordCount":330,"publisher":{"@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#organization"},"image":{"@id":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/eisai-and-biogen-introduce-leqembi-iqlik-for-alzheimer\/#primaryimage"},"thumbnailUrl":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/10\/Eisai-and-Biogen-Announce-U.S.-Availability-of-LEQEMBI\u00ae-IQLIK\u2122-lecanemab-irmb-Subcutaneous-Injection-Maintenance-Dose-for-Treatment-of-Early-Alzheimers-Disease.webp","keywords":["Alzheimer disease","Biogen","Eisai","LEQEMBI IQLIK","Pharma"],"articleSection":["APAC","Health Tech","Japan","News","Pharma","Regional"],"inLanguage":"ja"},{"@type":"WebPage","@id":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/eisai-and-biogen-introduce-leqembi-iqlik-for-alzheimer\/","url":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/eisai-and-biogen-introduce-leqembi-iqlik-for-alzheimer\/","name":"\u30a8\u30fc\u30b6\u30a4\u3068\u30d0\u30a4\u30aa\u30b8\u30a7\u30f3\u3001LEQEMBI IQLIK\u6ce8\u5c04\u5264\u3092\u65b0\u767a\u58f2","isPartOf":{"@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#website"},"primaryImageOfPage":{"@id":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/eisai-and-biogen-introduce-leqembi-iqlik-for-alzheimer\/#primaryimage"},"image":{"@id":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/eisai-and-biogen-introduce-leqembi-iqlik-for-alzheimer\/#primaryimage"},"thumbnailUrl":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/10\/Eisai-and-Biogen-Announce-U.S.-Availability-of-LEQEMBI\u00ae-IQLIK\u2122-lecanemab-irmb-Subcutaneous-Injection-Maintenance-Dose-for-Treatment-of-Early-Alzheimers-Disease.webp","datePublished":"2025-10-07T12:33:15+00:00","description":"\u30a8\u30fc\u30b6\u30a4\u3068\u30d0\u30a4\u30aa\u30b8\u30a7\u30f3\u793e\u3001\u65e9\u671f\u30a2\u30eb\u30c4\u30cf\u30a4\u30de\u30fc\u578b\u8a8d\u77e5\u75c7\u6cbb\u7642\u5264\u300cLEQEMBI\u00ae IQLIK\u2122\u300d\u3092\u90311\u56de\u76ae\u4e0b\u6ce8\u88fd\u5264\u3068\u3057\u3066\u767a\u58f2\u3001\u70b9\u6ef4\u9759\u6ce8\u306b\u4ee3\u308f\u308b\u6cbb\u7642\u6cd5\u3092\u63d0\u4f9b.","breadcrumb":{"@id":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/eisai-and-biogen-introduce-leqembi-iqlik-for-alzheimer\/#breadcrumb"},"inLanguage":"ja","potentialAction":[{"@type":"ReadAction","target":["https:\/\/itbusinesstoday.com\/health-tech\/pharma\/eisai-and-biogen-introduce-leqembi-iqlik-for-alzheimer\/"]}]},{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/eisai-and-biogen-introduce-leqembi-iqlik-for-alzheimer\/#primaryimage","url":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/10\/Eisai-and-Biogen-Announce-U.S.-Availability-of-LEQEMBI\u00ae-IQLIK\u2122-lecanemab-irmb-Subcutaneous-Injection-Maintenance-Dose-for-Treatment-of-Early-Alzheimers-Disease.webp","contentUrl":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/10\/Eisai-and-Biogen-Announce-U.S.-Availability-of-LEQEMBI\u00ae-IQLIK\u2122-lecanemab-irmb-Subcutaneous-Injection-Maintenance-Dose-for-Treatment-of-Early-Alzheimers-Disease.webp","width":1200,"height":800,"caption":"Eisai"},{"@type":"BreadcrumbList","@id":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/eisai-and-biogen-introduce-leqembi-iqlik-for-alzheimer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/itbusinesstoday.com\/"},{"@type":"ListItem","position":2,"name":"Eisai and Biogen introduce LEQEMBI IQLIK for Alzheimer"}]},{"@type":"WebSite","@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#website","url":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/","name":"\u30a4\u30c3\u30c8\u30d3\u30b8\u30cd\u30b9\u30c8\u30a5\u30c7\u30a4","description":"","publisher":{"@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"ja"},{"@type":"Organization","@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#organization","name":"\u30a4\u30c3\u30c8\u30d3\u30b8\u30cd\u30b9\u30c8\u30a5\u30c7\u30a4","url":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/","logo":{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#\/schema\/logo\/image\/","url":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/Asset-1.png","contentUrl":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/Asset-1.png","width":663,"height":275,"caption":"itbusinesstoday"},"image":{"@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#\/schema\/person\/94fb575e469aff25a4b938814d050f15","name":"ITBT\u30b9\u30bf\u30c3\u30d5\u30e9\u30a4\u30bf\u30fc","image":{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/Favicon-1.png90b3cb23d1d9c08733d969d29ea2d30d","url":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/Favicon-1.png","contentUrl":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/Favicon-1.png","caption":"ITBT StaffWriter"},"description":"ITBT\u30b9\u30bf\u30c3\u30d5\u30e9\u30a4\u30bf\u30fc\u306f\u3001IT Business Today\u306e\u793e\u5185\u5bc4\u7a3f\u8005\u3067\u3001\u30bf\u30a4\u30e0\u30ea\u30fc\u306a\u30cb\u30e5\u30fc\u30b9\u3068QuickBytes\u306e\u914d\u4fe1\u3092\u62c5\u5f53\u3057\u3066\u3044\u307e\u3059\u3002IT\u3001\u30cf\u30a4\u30c6\u30af\u3001\u4f01\u696d\u30bd\u30ea\u30e5\u30fc\u30b7\u30e7\u30f3\u306e\u6700\u65b0\u52d5\u5411\u3092\u30ab\u30d0\u30fc\u3057\u3001\u7c21\u6f54\u3067\u30a4\u30f3\u30d1\u30af\u30c8\u306e\u3042\u308b\u6700\u65b0\u60c5\u5831\u3092\u8aad\u8005\u306b\u63d0\u4f9b\u3057\u3066\u3044\u307e\u3059\u3002","sameAs":["https:\/\/itbusinesstoday.com\/"],"url":"https:\/\/itbusinesstoday.com\/ja\/author\/itbt-staffwriter\/"}]}},"authors":[{"term_id":572,"user_id":7,"is_guest":0,"slug":"itbt-staffwriter","display_name":"ITBT StaffWriter","avatar_url":{"url":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/Favicon-1.png","url2x":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/Favicon-1.png"},"author_category":"","first_name":"ITBT","last_name":"StaffWriter","user_url":"https:\/\/itbusinesstoday.com\/","job_title":"","description":"ITBT\u30b9\u30bf\u30c3\u30d5\u30e9\u30a4\u30bf\u30fc\u306f\u3001IT Business Today\u306e\u793e\u5185\u5bc4\u7a3f\u8005\u3067\u3001\u30bf\u30a4\u30e0\u30ea\u30fc\u306a\u30cb\u30e5\u30fc\u30b9\u3068QuickBytes\u306e\u914d\u4fe1\u3092\u62c5\u5f53\u3057\u3066\u3044\u307e\u3059\u3002IT\u3001\u30cf\u30a4\u30c6\u30af\u3001\u4f01\u696d\u30bd\u30ea\u30e5\u30fc\u30b7\u30e7\u30f3\u306e\u6700\u65b0\u52d5\u5411\u3092\u30ab\u30d0\u30fc\u3057\u3001\u7c21\u6f54\u3067\u30a4\u30f3\u30d1\u30af\u30c8\u306e\u3042\u308b\u6700\u65b0\u60c5\u5831\u3092\u8aad\u8005\u306b\u63d0\u4f9b\u3057\u3066\u3044\u307e\u3059\u3002"}],"_links":{"self":[{"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/posts\/22172","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/comments?post=22172"}],"version-history":[{"count":1,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/posts\/22172\/revisions"}],"predecessor-version":[{"id":22174,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/posts\/22172\/revisions\/22174"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/media\/22173"}],"wp:attachment":[{"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/media?parent=22172"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/categories?post=22172"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/tags?post=22172"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/ppma_author?post=22172"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}